Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

IPO Prophet® is a real-time IPO intelligence platform that gives investors a data-driven edge. Our team brings over 75 years of combined experience trading and investing in IPOs, translating firsthand market execution into proprietary quantitative analytics designed for today’s issuance environment.

Unlike traditional research providers that rely solely on commentary and retrospective analysis, IPO Prophet® is grounded in actual trading experience across multiple IPO cycles. Our platform integrates live market data, historical performance benchmarks, and predictive models to help investors evaluate deal quality, pricing discipline, demand strength, and post-IPO trading behavior as it unfolds.

From pre-deal analysis through pricing and aftermarket performance, IPO Prophet® delivers actionable, data-driven intelligence that helps investors make informed decisions at the moments that matter most.

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

<ul><li>Braveheart Bio, Inc. (NASDAQ: BRVE) delivered one of the strongest biotechnology IPO performances of 2026, with shares closing at $29.80, up 65.56% from the $18.00 IPO price after opening at $30.20.</li><li>The company raised approximately $306 million through the sale of 17.0 million shares, pricing at the top of its marketed $16.00 to $18.00 range.</li><li>The offering values Braveheart at an implied market capitalization of roughly $2.1 billion at the close of its first trading session and was led by J.P. Morgan, Jefferies, Leerink Partners, Guggenheim Securities, and Chardan.</li></ul>

Braveheart Bio, Inc. (NASDAQ: BRVE) delivered one of the strongest biotechnology IPO performances of 2026, with shares closing at $29.80, up 65.56% from the $18.00 IPO price after opening at $30.20.The company raised approximately $306 million through the sale of 17.0 million shares, pricing at the top of its marketed $16.00 to $18.00 range.The offering values Braveheart at an implied market capitalization of roughly $2.1 billion at the close of its first trading session and was led by J.P. Morgan, Jefferies, Leerink Partners, Guggenheim Securities, and Chardan.

Braveheart Bio (BRVE) Surges 66% in IPO Debut as Investors Embrace Precision Cardiovascular Medicine